Pluvicto® Approval Marks a Major Step Forward in mHSPC

Pluvicto has received regulatory approval for treatment in metastatic hormone-sensitive prostate cancer (mHSPC), representing a significant advancement in therapeutic options for this condition.

This Wire brief sits within Fusion42's coverage of Health: Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.